In Depth 5 Dec 2024
The biggest private biotech investments in November 2024
The companies Metsera, Alentis Therapeutics, and Adcendo bagged the biggest private biotech investments in November 2024.
- Latest Posts
Best in Biotech 5 Dec 2024
Five biosimilar companies you should know about
Discover five biosimilar companies creating affordable versions of blockbuster drugs and hoping to capitalize on the upcoming patent cliff.
In Depth 4 Dec 2024
Idiopathic pulmonary fibrosis: Refoxy, Boehringer, Insilico, and more on the hunt for curative treatments
There is a lot of research going on in the therapeutic field of idiopathic pulmonary fibrosis, in the hope that more treatments reach patients sooner.
Best in Biotech 3 Dec 2024
Twelve gift ideas for a biotech enthusiast this holiday season
Explore our curated list of biotechnology-themed gifts, ranging from captivating board games to engaging DIY biology kits.
Process intensification: Fueling biopharma success at warp speed
Learn about process intensification in biopharma, key strategies for success, and solutions to overcome manufacturing challenges.
In Depth 2 Dec 2024
The rise of cancer vaccines: A new era in immunotherapy
Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight tumors.
ADVERTISEMENT
ADVERTISEMENT
News and Trends 29 Nov 2024
Trump’s healthcare picks: Who they are and what they mean for the biopharma industry
Trump’s nominees for top healthcare roles have sparked significant debate. So, what do their appointments signal for the future of healthcare in the U.S.?
Podcast 29 Nov 2024
Can biotech beat mosquito-borne diseases?
With mosquito-borne diseases on the rise, Oxitec’s Friendly mosquitoes are designed to suppress populations of disease-spreading mosquitoes.
Best in Biotech 28 Nov 2024
Six antisense oligonucleotide companies shaping the future of genetic medicine
Learn more about six antisense oligonucleotide companies shaping the future of genetic medicine, just as the market is expected to grow.
In Depth 27 Nov 2024
Charcot–Marie–Tooth disease: what’s going on in the clinical field?
In this article, we take a look at the various treatments in development to address the unmet needs of people with Charcot–Marie–Tooth disease.
Best in Biotech 26 Nov 2024
Seven miRNA-focused companies pioneering new therapies in 2024
Delve into the field of miRNA with seven companies with miRNA-focused candidates in the pipeline in 2024, from oncology to neurodegeneration.
Harnessing antibody-drug conjugates (ADCs) in oncology: Pathways to clinical success
Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of cancer treatment.
ADVERTISEMENT
